Dean Harvey Comments on FTC’s New Challenge to No-Authorized-Generic Drug Agreements

Dean Harvey Comments on FTC's New Challenge to No-Authorized-Generic Drug Agreements

The Federal Trade Commission (FTC) has made its first outright challenge towards so-called “no-authorized-generics” agreements between branded drug makers and generic drug companies. The agency initiated legal action against Endo Pharmaceuticals Inc. and other drugmakers for making anti-competitive payments through the mechanism of illegally withholding authorization for the production of generic versions of certain drugs. The FTC concludes these pharmaceutical companies violated antitrust laws by blocking lower-cost generic versions of branded drugs from consumers with pay-for-delay payments.

[Read more…]